University Hospitals Birmingham NHS Foundation Trust (UHB) and AI specialist Skin Analytics will pilot a new community assessment service for skin cancer, as they look to reduce delays in the detection and treatment of skin cancer that might occur during the coronavirus pandemic.
Melanoma is the fifth most common cancer in Britain, killing around 2,300 people each year. However, with early diagnosis, survival rates are significantly improves. With a tele-dermatology service, patients who are referred to UHB can have potentially cancerous lesions assessed and receive treatment, which could be life-saving, sooner.
Patients referred in the pilot will receive a skin cancer triage outside of the hospital, with AI technology utilised to capture high quality images of lesions, some of which may be melanoma and require urgent investigation from a dermatologist and some of which may be safe to defer.
In the here and now, it is hoped that the service may help flatten the demand curve and manage the ongoing clinical risk when coronavirus social isolation and distancing measures are lifted and latent demand emerges. Should the pilot be successful, the model could be considered for the benefit of future patients.
The AI triage service is powered by Skin Analytics DERM solution. This is a clinically validated and CE certified medical solution that can be used to identify 11 lesion types including Melanoma, Non-Melanoma skin cancers, Precancerous lesions and benign lesions.